[HTML][HTML] Signaling pathways and targeted therapies for psoriasis

J Guo, H Zhang, W Lin, L Lu, J Su… - Signal Transduction and …, 2023 - nature.com
Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on
individuals, health systems, and society worldwide. With the immunological pathologies and …

Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis

PO Perche, MK Cook… - Annals of …, 2023 - journals.sagepub.com
Objective The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1
inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD). Data …

Biological therapies for atopic dermatitis: a systematic review

S Zhou, F Qi, Y Gong, J Zhang, B Zhu - Dermatology, 2021 - karger.com
Background: Atopic dermatitis (AD) is a widely acquired, relapsing inflammatory skin
disease. Biologics are now widely used in patients with moderate-to-severe AD. Objective …

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders

P Xu, P Shen, B Yu, X Xu, R Ge, X Cheng… - European Journal of …, 2020 - Elsevier
Abstract The Janus kinases or JAKs are a family of intracellular tyrosine kinases that play an
essential role in the signaling of numerous cytokines that have been implicated in the …

[HTML][HTML] Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные

ЕЛ Насонов, АС Авдеева - Научно-практическая ревматология, 2019 - cyberleninka.ru
Иммуновоспалительные ревматические заболевания (ИВРЗ)-большая группа
патологических состояний, в основе которых лежит нарушение иммунологической …

[HTML][HTML] Novel immunological and genetic factors associated with vitiligo: A review

SL Said-Fernandez… - Experimental and …, 2021 - spandidos-publications.com
Vitiligo is a skin disorder characterized by depigmentation of the skin due to a lack of
melanin. This condition affects men and woman of all ages and its incidence is not restricted …

A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders

Y Kalantari, S Sadeghi, D Asadi, A Goodarzi - International …, 2022 - Elsevier
Janus kinases (JAKs) are a group of intracytoplasmic tyrosine kinase proteins that bind to
the cytoplasmic part of the transmembrane cytokine receptors and regulate signaling. The …

TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors

CE Jo, M Gooderham, J Beecker - International Journal of …, 2022 - Wiley Online Library
Increasing understanding of cytokines as major drivers of immune‐mediated diseases has
revolutionized targeted treatments for these conditions. As the pathogenesis of autoimmune …

Advances in understanding of Netherton syndrome and therapeutic implications

E Petrova, A Hovnanian - Expert Opinion on Orphan Drugs, 2020 - Taylor & Francis
Introduction: Netherton syndrome (NS) is a rare and severe ichthyosis characterized by
superficial scaling, skin inflammation, a specific hair shaft defect, severe atopic …

Pharmacological therapies and drug development targeting SARS-CoV-2 infection

Y Jiang, L Rubin, Z Zhou, H Zhang, Q Su… - Cytokine & Growth …, 2022 - Elsevier
The development of therapies for SARS-CoV-2 infection, based on virus biology and
pathology, and of large-and small-scale randomized controlled trials, have brought forward …